X4 Pharmaceuticals Inc (XFOR) — Titan Protect Analysis

XFOR

X4 Pharmaceuticals Inc

Healthcare · ·

$3.83

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$385M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.47

Based on estimated future earnings — lower means cheaper

Rev Growth

-90.6%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-104.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+213% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufac

https://www.x4pharma.com

Country: United States Employees: 45 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.125

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0338

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.679

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-65.0%

Historical annualised return based on price data

Max Drawdown

-95.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.32

Very low correlation to market moves

52W High

$4.83

21% below the year high

52W Low

$1.35

184% above the year low

Avg Volume

423,252

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.07

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

45.86

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

81.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-748.5%

Profit from core operations before interest and tax

Free Cash Flow

$-55,171,752

Negative — the business is spending more than it generates

Revenue (TTM)

$9M

Total revenue over the last 12 months

Net Income

$-99,722,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$13.00

Target Median

$12.00

Target Low

$10.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
26 Feb2025	Daniel Webster	Republican	sell	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go